Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Fulvestrant and Anastrozole as Neoadjuvant Therapy in HR+ Breast Cancer
NCT00921115Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- May 2009
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in Invasive breast cancer (IBC), sponsored by University of Kansas Medical Center. Primary endpoint: Pathologic Complete Response Rate at 4 months. Started May 2009; status: completed.
02
Drugs
fulvestrant
03
Conditions
Invasive breast cancer (IBC)
Beyond the preview
Go deeper on NCT00921115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921115.